# Skopos Bio

Source: https://onco.cc/companies/skopos-bio/  
OnCo record `skopos-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Skopos Bio is a Melbourne spin-out from the Peter MacCallum Cancer Centre developing radioactive drugs that home in on cancer cells, including targets ordinary drugs struggle to reach. It launched in October 2026 with seed funding to reach first human trials.

## Summary

Skopos Bio is a spin-out from the Peter MacCallum Cancer Centre in Melbourne, based at the Jumar Bioincubator, developing next-generation radiopharmaceutical therapies. Its founders are Professor Michael Hofman, Associate Professor Mohammad Haskali and Associate Professor Luc Furic. It announced its launch in early October 2026 with an AUD 12 million seed round led by Tenmile, Tin Alley Ventures and Yosemite, intended to take its first programme into human trials. Targets and isotopes have not been disclosed.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Melbourne, VIC
- Type: radiopharma
- Website: https://www.skoposbio.com/

## Notes

- The company website names the investors but gives no amount, date or founding year; SmartCompany says the founders formed the company in 2024. Founding year not stated by the company.

## Sources

- Official website: https://www.skoposbio.com/
- SmartCompany: seed round: https://smartcompany.com.au/startupsmart/three-aussie-startups-that-raised-18-75-million-this-week

## Connected records

- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)

---
JSON: https://onco.cc/api/v1/entities/skopos-bio.json